Prophylaxis and treatment of bacterial infections: Do we need new strategies?

Reviews in Clinical and Experimental Hematology

Volumn 9, Issue 2, 2005, Pages

  Alessandra, Micozzi ^a   Giampaolo, Bucaneve ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO MONTELUCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; MEROPENEM; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; DRUG COST; FEBRILE NEUTROPENIA; FEVER; GRAM NEGATIVE INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; MORTALITY; REVIEW;

EID: 33745009260     PISSN: 1825151X     EISSN: 1825151X     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol, 10: 316-322, 1992.
2. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 18: 3038-3051, 2000.
3. Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother, 38: 1363-1367, 1994.
4. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis, 7: 327-332, 2001.
5. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis, 32 (Suppl. 2): 114-132, 2001.
6. Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn Microbiol Infect Dis, 47: 435-4 45, 2003.
7. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med, 353: 977-987, 2005.
8. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med, 353: 988-998, 2005.
9. Van der Waaij D Selective decontamination of the digestive tract: general principles. Eur J Cancer Clin Oncol, 24 (Suppl. 1): S1-4, 1988.
10. Gurwith MJ, Brunton JL, Lank BA, et al. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med, 66: 248-256, 1979.
11. Dekker AW, Rozenberg-Arska M, Sixma JJ, Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med, 95: 555-559, 1981.
12. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. J Infect Dis, 150: 372-379, 1984.
13. Enno A, Catovsky D, Darrell J, et al. Co-trimoxazole for prevention of infection in acute leukaemia. Lancet, 2: 395-397, 1978.
14. Starke ID, Donnelly P, Catovsky D, et al. Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukaemia. Lancet, 1: 5-6, 1982.
15. Winston DJ, Ho WG, Nakao SL, et al. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med, 80: 884-890, 1986.
16. Winston DJ, Ho WG, Bruckner DA, et al. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med, 88: 36-42, 1990.
17. Bow EJ, Ravner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med, 84: 847-854, 1988.
18. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med, 106: 7-11, 1987.
19. Donnelly JP, Maschmeyer G, Daenen S. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukaemia-ciprofloxacin versus co-trimoxazole plus colistin. The EORTC-Gnotobiotic Project Group. Eur J Cancer, 28A: 873-878, 1992.
20. Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, Todd D. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother, 34: 215-218, 1990.
21. Kern W, Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection, 19: 73-80, 1991.
22. Jansen J, Cromer M, Akard L, Black JR, Wheat LJ, Allen SD.Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med, 96: 335-341, 1994.
23. Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone- resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother, 38: 681-687, 1994.
24. Carratala J, Fernandez-Sevilla A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis, 20: 557-560, discussion 561-563, 1995.
25. Somolinos N, Arranz R, Del Rey MC, Jimenez ML. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J Antimicrob Chemother, 30: 730-731, 1992.
26. Razonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin. Clin Infect Dis, 34: 1469-1474, 2002.
27. Wimperis JZ, Baglin TP, Marcus RE, Warren RE. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant, 8: 363-367, 1991.
28. Kern WV, Hay B, Kern P, Marre R, Arnold R. A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother, 38: 465-472, 1994.
29. Broun ER, Wheat JL, Kneebone PH, et al. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.Antimicrob Agents Chemother, 38: 576-579, 1994.
30. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA, 272: 1183-1189, 1994.
31. Fanci R, Leoni F, Bosi A, et al. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin. J Chemother, 5: 119-123, 1993.
32. Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med, 125: 183-190, 1996.
33. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 34: 730-751, 2002.
34. Sleijfer DT, Mulder NH, de vries-Hospers HG, et al. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer, 16: 859-869, 1980.
35. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 106: 1-7, 1987.
36. Hartlapp JH. Antimicrobial prophylaxis in immunocompromised patients. Drugs, 34 (Suppl. 1): 131-133, 1987.
37. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation, 51: 630-636, 1991.
38. Sampi K, Maseki N, Hattori M. A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study. Gan To Kagaku Ryoho, 19: 823-826, 1992.
39. Shhroeder M, Schessel C, Selbach J, Westerhausen M. Antibiotic prophylaxis with gyrase inhibitors durin cytostatically induced granulocytopenias in patients with solid tumors a double-blind prospective randomized study. Onkologie, 15: 476-479, 1992.
40. Maiche AG, Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer, 29A: 1403-1405, 1993.
41. Talbot GH, Casileth PA, Paradiso L, et al. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother, 37: 474-482, 1993.
42. Yamada T, Dan K, Nomura T. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med, 32: 710-715, 1993.
43. Brodsky AL, Minissale CJ, Melero MJ, Sanchez Avalos JC. Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires), 53: 401-407, 1993.
44. Carlson JW, Fowler JM, Mitchell SK, et al. Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecol Oncol, 65: 325-329, 1997.
45. Casali A, Veri C, Paoletti G, et al. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia, 7: 327-329, 1988.
46. Thomas X, Troncy J, Belhabri A, et al. Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study. Presse Med, 29: 1745-1751, 2000.
47. Tjan-HeiJnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol, 12: 1359-1368, 2001.
48. Nenova IS, Ananostev NH, Goranov SE, et al. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv), 43: 40-45, 2001.
49. Tsutani H, Imamura S, Ueda T, Yoshida H, Iwasaki H, Fukushima T et al. Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy. Intern Med, 31: 319-324, 1992.
50. Lee DG, Choi SM, Choi JH, et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med, 17: 38-44, 2002.
51. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med, 142: 979-995, 2005.
52. van de Wetering MD, de Witte MA, Kremer LCM, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer, 41: 1372-1382, 2005.
53. Engels EA, Lau J and Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol, 16: 1179-1187, 1998.
54. Cruciani M, Randazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis, 23: 795-805, 1996.
55. Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the additino of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol, 21: 4127-4137, 2003.
56. Martino R, Subira M, Altes A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol, 99: 206-211, 1998.
57. Kern WV, Klose K, Jellen Ritter AS, et al. Fluoroquinolones resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis, 24: 111-118, 2005.
58. Freifeld A, Marchigiani D, Walsh T, et al. A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy. N Engl J Med, 341: 305-311, 1999.
59. Kern WV, Cometta A, de Bock R, et al. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy. N Engl J Med, 341: 312-318, 1999.
60. Maschmeyer G, Link H, Hiddenmann W, et al. Interventional antimicrobial strategy in febrile neutropenic patients. Results of a multicenter study in 1260 patients with hematological malignancies. The Interventional Antimicrobial Strategy Study Group, Paul Erlich Society for Chemotherapy. Onkologie (Oncology), 13: 38-42, 1990.
61. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol, 82 (Suppl 2): S105-117, 2003.
62. Klastersky J. Sensitivity to antibiotics of gram-negative pathogens isolated from hospitalized patients having disseminated malignant disease. Eur J Cancer, 7: 411-417, 1971.
63. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother, 40: 1108-1115, 1996.
64. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis, 33: 1295-1301, 2001.
65. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis, 36: 1103-1110, 2003.
66. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis, 25: 247-259, 1997.
67. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C β-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis, 28: 211-219, 1997.
68. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis, 36: 149-158, 2003.
69. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research, Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Int Med, 119: 584-593, 1993.
70. Cometta A, Zinner S, de Bock R, et al, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother, 39: 445-452, 1995.
71. Hess U, Bohme C, Rey K et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer, 6: 402-409, 1998.
72. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, 3. John Wiley & Sons, Ltd., Chichester, UK, 2004.
73. Paul M, Soares-Weiser K, Leibovici L. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J, 326: 1111-1115, 2003.
74. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother, 34: 989-995, 2000.
75. Cherif H, Bjorkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis, 36: 593-600, 2004.
76. Feld R, DePauw B, Berman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol, 18: 3690-3698, 2000.
77. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol, 13: 165-176, 1995.
78. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother, 34: 1336-1341, 1990.
79. Lindblad R, Rodjer S, Adriansson M et al. Empiric monotherapy for febrile neutropenia - a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis, 30: 237-243, 1998.
80. Oppenheim BA, Morgenstern GR, Chang J, et al. Safety and efficacy of piperacillin/tazobactam versus meropenem in the treatment of febrile neutropenia. J Infect, 43: A67, 2001.
81. Raad, II, Escalante C, Hachem RY et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer, 98: 1039-1047, 2003.
82. Tamura K, Matsuoka H, Tsukada J, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol, 71: 248-255, 2002.
83. Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol, 79: 152-157, 2000.
84. Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother, 42: 511-518, 1998.
85. Bodey GP, Fainstein V, Elting LS, et al. β-Lactam regimens for the febrile neutropenic patient. Cancer, 65: 9-16, 1990.
86. Bodey G, Abi-Said D, Rolston K, et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis, 15: 625-634, 1996.
87. Bohme A, Shah PM, Stille W et al. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res, 3: 324-330, 1998.
88. Boogaerts MA, Demuynck H, Mestdagh N, et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother, 36: 185-200, 1995.
89. Paul M, Yahav D, Fraser A et al. Single-agent antibiotic therapy for the initial, empirical, treatment of febrile neutropenia: comparison of β-lactams. (Protocol). Cochrane Database Sys Rev, 2: Art. No. CD005197, 2005.
90. Pico JL, Marie JP, Chice D, et al. Should vancomycin be used empirically in febbrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med, 2: 275-280, 1993.
91. Dompeling EC, Donnelly JP, Deresinski SC, et al. Early identification of neutropenic patients at risk of grampositive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer, 32A: 1332-1339, 1996.
92. European Organization for Research, Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group, the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis, 163: 951-958, 1991.
93. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Int Med, 108: 30-35, 1988.
94. Del Favero A, Menichetti F, Guerciolini R, et al. Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. Antimicrob Agents Chemother, 31: 1126-1129, 1987.
95. Lim S, Smith MP, Goldstone AH, Machin SJ. A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. Br J Haematol, 76 (Suppl. 2): 41-44, 1990.
96. Novakova I, Donnelly JP, De Pauw B. Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother, 35: 672-678, 1991.
97. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother, 36: 1062-1067, 1992.
98. Martino P, Micozzi A, Gentile G, et al. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis, 15: 290-294, 1992.
99. Karp JE, Dick JD, Angelopulos C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med, 81: 237-242, 1986.
100. Micozzi A, Venditti M, Amadori S, et al. Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients. Br J Haematol, 76 (Suppl. 2): 19-23, 1990.
101. Press OW, Ramsey PG, Larson EB, et al. Hickman catheter infections in patients with malignancies. Medicine (Baltimore), 63: 189-200, 1984.
102. Fatkenheuer G, Buchheidt D, Cornely OA, et al. Central venous catheter (CVC)-related infections in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol, 82 (Suppl. 2): S149-157, 2003.
103. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother, 55: 436-444, 2005.
104. Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis, 5: 431-439, 2005.
105. De Pauw BE, Novakova IR, Donnelly JP. Options and limitations of teicoplanin in febrile granulocytopenic patients. Br J Haematol, 76 (Suppl. 2): 1-5, 1990.
106. Novakova IR, Donnelly JP, Verhagen CS, De Pauw BE. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother, 25: 985-993, 1990.
107. Erjavec Z, de Vries-Hospers HG, Laseur M, et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother, 45: 843-849, 2000.
108. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis, 37: 382-389, 2003.
109. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis,; 18: 539-544, 1999.
110. Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect, 42: 120-125, 2001.
111. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103: 1916-1924, 2005.